Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Apr 15, 2020	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0001209191-20-024475.pdf 0001209191-20-024475.rtf 0001209191-20-024475.xls View HTML
Apr 15, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-20-024480.pdf 0001209191-20-024480.rtf 0001209191-20-024480.xls View HTML
Mar 30, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	0001564590-20-013845.pdf 0001564590-20-013845.rtf 0001564590-20-013845.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 30, 2020	Annual report which provides a comprehensive overview of the company for the past year	10-K	Annual Filings	0001564590-20-013856.pdf 0001564590-20-013856.rtf 0001564590-20-013856.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 30, 2020	Pre-effective amendment to an S-3 filing	S-3/A	Registration Statements	0001193125-20-090086.pdf 0001193125-20-090086.rtf 0001193125-20-090086.xls View HTML
Mar 30, 2020	Securities offered to employees pursuant to employee benefit plans	S-8	Registration Statements	0001193125-20-091059.pdf 0001193125-20-091059.rtf 0001193125-20-091059.xls View HTML
Mar 27, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-20-021382.pdf 0001209191-20-021382.rtf 0001209191-20-021382.xls View HTML
Mar 27, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-20-021379.pdf 0001209191-20-021379.rtf 0001209191-20-021379.xls View HTML
Mar 27, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-20-021376.pdf 0001209191-20-021376.rtf 0001209191-20-021376.xls View HTML
Mar 27, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-20-021385.pdf 0001209191-20-021385.rtf 0001209191-20-021385.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.